#Ivf

A new international study provides striking evidence that cannabis exposure could affect female fertility at the cellular level and may lower the likelihood of producing chromosomally normal embryos in IVF. The research, published in a leading science journal, combined a retrospective clinical analysis of follicular fluid from patients undergoing IVF with a laboratory investigation using immature human egg cells. In the clinical arm, researchers detected traces of THC, the main psychoactive component of cannabis, in a small but notable portion of follicular fluid samples. In the lab arm, they exposed immature egg cells to THC and examined how these cells mature, how their chromosomes align, and how their gene expression changes. Taken together, the study suggests that cannabis exposure could be linked to changes in oocyte maturation, chromosome segregation, and ultimately the chromosomal health of embryos.

A groundbreaking study from the University of Toronto raises a cautionary flag for anyone undergoing in vitro fertilization (IVF): high levels of cannabis exposure may be linked to chromosomal abnormalities in eggs used for IVF. Researchers tested 1,059 samples of follicular fluid—the fluid surrounding developing eggs—and found that 62 samples contained tetrahydrocannabinol, the main psychoactive component of cannabis. In fluids with detectable THC, immature egg cells tended to show more chromosomal abnormalities, and these eggs tended to mature faster than those without THC. The researchers then repeated some experiments with eggs from 24 consenting patients and observed a similar pattern: unfertilized eggs exposed to THC concentrations higher than the study’s average exhibited nearly 10 percent more chromosome errors and reached maturation more quickly. While the findings point to a potential reproductive risk, the study authors caution that the small sample size means other factors, most notably age, could influence results and were not fully controlled.

A new fertility approach called Restorative Reproductive Medicine (RRM) has entered the public conversation as clinics promise to restore the body’s natural ability to conceive, offering what proponents call a gentler, more holistic alternative to in vitro fertilization. Yet behind the glossy marketing lies a storm of questions about evidence, safety, and regulation. For Thai families facing infertility, the stakes are personal: hopes for a child collide with concerns about cost, clarity, and whether these therapies are truly proven.

A new wave of technological advances promises parents a chance to have “high-quality” families by screening embryos for optimal genetic health, but current research and social debate show that the quest for genetic perfection may come at significant ethical, cultural, and emotional costs. As genetic screening companies like Orchid promote the ability to select embryos free from a wide array of health risks, a chorus of bioethicists, parents, and social critics warn that this trend risks making children into consumer products and overlooks the unpredictability—and inherent value—of imperfect human lives (The Dispatch).

Recent advances in genetic screening give parents the option to choose embryos based on health profiles. While this could reduce certain illnesses, experts warn that chasing genetic perfection may bring ethical, cultural, and emotional costs for families and society. In Thailand, preimplantation genetic testing (PGT) is increasingly offered as an add-on in IVF, shifting the conversation from possibility to broader questions about value, diversity, and compassion.

Thailand stands at a crossroads of medical tourism and evolving social norms around family and reproduction. Policymakers and communities must weigh technological capability against cultural values, social equity, and acceptance of difference.

A new study published by BMC Public Health has revealed a dramatic rise in public attention toward infertility in China, using Baidu search data to map nationwide trends and public sentiment around reproductive health issues. As infertility rates have soared from 7.5% in 2007 to an estimated 18.2% in 2020—now affecting one in five Chinese couples of reproductive age—the demand for information and solutions is reaching new heights, underscoring both societal anxieties and gaps in healthcare infrastructure. The findings provide powerful insights for Thai policymakers and families as Thailand faces similar demographic transitions and a shifting culture around fertility and family planning.

A recent study in BMC Public Health analyzes Baidu search trends to understand how people in China seek information about infertility, IVF, and related topics. The findings show infertility rates rising from 7.5% in 2007 to about 18.2% in 2020, suggesting roughly one in five couples of reproductive age could be affected. The research highlights public demand for information and gaps in healthcare infrastructure, offering timely lessons for Thailand as it navigates similar demographic and cultural shifts around fertility.

A landmark achievement in fertility medicine has been announced as artificial intelligence is credited with helping a couple conceive after 18 years of unsuccessful attempts—a result that could reshape options for millions facing male infertility worldwide. The couple, who struggled with repeated in vitro fertilization (IVF) failures due to the husband’s azoospermia, a severe condition where no measurable sperm are present in semen, finally found success at the Columbia University Fertility Center thanks to a pioneering AI-powered solution known as the STAR method. The case represents the first documented pregnancy enabled by this technology, igniting a new conversation about AI’s growing role in reproductive health (CNN).

A breakthrough in fertility treatment is offering renewed hope for Thai couples dealing with infertility, including azoospermia. Researchers at a premier fertility center used artificial intelligence to help a couple conceive after 18 years of trying. The method, STAR—Sperm Tracking and Recovery—uses AI to identify and retrieve sperm that are nearly invisible to the naked eye, providing a non-invasive alternative to traditional, emotionally demanding procedures.

Male infertility is a global concern, and Thailand is no exception. Data from leading health institutes suggest up to 40% of infertility cases involve male factors, with about 10% of infertile men diagnosed as azoospermic. In Thai society, where family lineage and continuity are highly valued, infertility can carry a heavy social stigma. This reality makes the journey toward parenthood especially challenging, and conventional options such as surgical sperm retrieval or donor sperm can pose emotional and cultural hurdles for many Thai families.

A sweeping purge of staff at the US Department of Health and Human Services’ (HHS) Division of Reproductive Health has ignited alarm among public health experts, advocates, and former officials, amid fears that the essential infrastructure supporting maternal, infant, and fertility care is now in jeopardy. More than 100 employees were abruptly dismissed this week, gutting teams mandated by federal law to collect and analyze data critical to healthy pregnancies, maternal outcomes, and assisted reproduction—including in vitro fertilization (IVF) support—according to multiple former staffers interviewed by Mother Jones (source).

A sweeping staff purge within the US Department of Health and Human Services’ Division of Reproductive Health has unsettled public health experts and advocates. More than 100 employees were dismissed this week, including specialists who maintain national data on pregnancies, maternal outcomes, and fertility treatment. The changes threaten the data infrastructure that underpins prenatal care, contraception access, and IVF-related research and guidance.

This development comes after President Trump’s public calls to expand family planning and improve IVF access. Observers note the contrast between campaign messaging about supporting mothers and families and the abrupt dismantling of a federal unit tasked with implementing those goals.

The global women’s health sector is witnessing an unprecedented boom, with its market value projected to soar from US$250-300 billion in 2023 to an estimated US$500 billion by 2030, according to an analysis published by BDA Partners on April 21, 2025. This rapid expansion—averaging an impressive 10% annual growth rate—signals not just increased investment in reproductive health but also heightened interest in a diverse spectrum of conditions affecting women, presenting significant opportunities and challenges for countries like Thailand aiming to boost healthcare equity and quality for women nationwide (BDA Partners).

The global women’s health market is accelerating rapidly. A recent BDA Partners analysis shows the sector could grow from about US$250–300 billion in 2023 to around US$500 billion by 2030, a healthy 10% average annual increase. This expansion reflects broader investment in women’s health beyond IVF, spanning heart health, osteoporosis, endocrine disorders, and mental well-being. In Thailand, this shift offers a path to better health equity and access for women nationwide, backed by policy and private investment.

As more Thai couples and individuals consider starting families later in life, questions about fertility—especially egg quality—are on the rise. Popular wisdom and online advice often tout lifestyle tweaks, diets, or supplements as the magic keys to improving fertility. But does the science back up these claims? According to a comprehensive review of recent research, including a widely cited article from SELF and several new studies in 2024, the answer is nuanced. While age remains the single most influential factor, certain everyday habits may indeed nudge the odds—though not as much as many would hope.

As Thai couples increasingly consider delaying parenthood, questions about fertility and egg health have surged. Online advice often promises quick fixes through diet, supplements, or “miracle” routines. New research, including recent reviews and 2024 studies, shows a nuanced picture: age remains the strongest factor, but certain daily habits may modestly improve outcomes when combined with medical care.

Egg quality matters as much as quantity. High-quality eggs carry the right chromosomes and robust mitochondria to support fertilization and embryo development. Age is the primary driver of decline; after 35, both the number and quality of eggs diminish, increasing the risk of infertility, miscarriage, and chromosomal issues. Conditions such as endometriosis, PCOS, or cancer therapies can further affect egg quality, according to research from major outlets and peer-reviewed journals cited in recent reviews.